secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001711279-25-000029
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech announces EC approval of VYJUVEK for DEB; launch in Germany mid-2025
--------------------------------------------------------------------------------

- EC granted marketing authorization for VYJUVEK (beremagene geperpavec-svdt) to treat DEB from birth.
- Flexible dosing: at home or healthcare setting; patient/caregiver administration if appropriate.
- First corrective medicine for DEB in Europe; launch in Germany mid-2025; 1,000 DEB patients identified in France and Germany.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000029/0001711279-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000029/krys-20250428.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer